Internal Medicine Department, Hepatology Division.
Diagnostic Radiology Department.
Eur J Gastroenterol Hepatol. 2019 Oct;31(10):1275-1282. doi: 10.1097/MEG.0000000000001459.
Clinical worsening after achieving a sustained virological response (SVR) needs to be clarified and explained. Persistence of hepatitis C virus (HCV) core antigen interacts with the host proteins to interfere with signaling pathways and increases the susceptibility to hepatic carcinogenesis.
This study aimed to investigate the risk factors that increase the progression of liver disease and hepatocellular carcinoma in a subgroup of HCV patients who achieved a SVR.
Eighty-nine HCV patients with hepatic decompensation were selected 8.2 ± 1.8 months after achieving SVR24. HCV core antigen and HCV RNA were detected in peripheral blood mononuclear cells. Matched control (n = 100) and training (n = 200) groups were recruited.
Eighty-five patients showed a progression of Child-Turcotte-Pugh and model for end-stage liver disease scores, with positive RNA in peripheral blood mononuclear cell (357.4 ± 42.1 IU/million cell) and positive hepatitis C virus core antigen (n = 73); four patients were excluded. Susceptibility to decompensation and hepatocellular carcinoma after direct-acting antiviral drugs increased with age [odds ratio (OD) = 1.87], and was associated with male sex (OD = 1.65), diabetes (OD = 3.68), thrombocytopenia (OD = 2.44), pretreatment Alfa-fetoprotein (OD = 3.41), and occult HCV (OD = 4.1).
Clinical deterioration after SVR could be explained by occult HCV mainly in older male patients with diabetes and thrombocytopenia.
达到持续病毒学应答(SVR)后临床恶化需要阐明和解释。丙型肝炎病毒(HCV)核心抗原的持续存在与宿主蛋白相互作用,干扰信号通路,增加肝致癌的易感性。
本研究旨在调查在达到 SVR 的 HCV 患者亚组中,增加肝病和肝细胞癌进展的风险因素。
选择 89 例 SVR24 后 8.2±1.8 个月出现肝失代偿的 HCV 患者。检测外周血单个核细胞中的 HCV 核心抗原和 HCV RNA。招募了匹配的对照组(n=100)和训练组(n=200)。
85 例患者出现了 Child-Turcotte-Pugh 和终末期肝病模型评分的进展,外周血单个核细胞 RNA 阳性(357.4±42.1 IU/百万细胞)和 HCV 核心抗原阳性(n=73);排除了 4 例患者。直接作用抗病毒药物后易发生失代偿和肝细胞癌的风险随着年龄的增长而增加[比值比(OR)=1.87],与男性(OR=1.65)、糖尿病(OR=3.68)、血小板减少症(OR=2.44)、治疗前甲胎蛋白(OR=3.41)和隐匿性 HCV(OR=4.1)有关。
SVR 后临床恶化可以用隐匿性 HCV 来解释,主要发生在年龄较大的男性糖尿病和血小板减少症患者中。